Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Verbinnen

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
The Journal of Antimicrobial Chemotherapy|January 18, 2022
Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infectionEd J Gane, Christian Schwabe, Elina Berliba, et al.
Antimicrobial Agents and Chemotherapy|January 28, 2009
In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitorTse-I Lin, Oliver Lenz, Gregory Fanning, et al.
Environmental Toxicology and Chemistry|July 29, 2024
Occurrence and Environmental Risk Assessment of Contaminants of Emerging Concern in Brazilian Surface WatersThiessa M A Oliveira, Adrislaine S Mansano, Carlos A Holanda, et al.
Gut|November 5, 2025
Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT studyPatrick T F Kennedy, Scott Fung, Maria Buti, et al.
Clinical & Translational Immunology|April 22, 2026
An Ad26-MVA-BN-based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infectionsSelina Khan, Satish Boedhoe, Miranda Baert, et al.
Gastroenterology|April 29, 2020
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic InfectionFabien Zoulim, Oliver Lenz, Joris J Vandenbossche, et al.
The Lancet. Infectious Diseases|December 9, 2014
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trialK Rajender Reddy, Stefan Zeuzem, Fabien Zoulim, et al.
Journal of Hepatology|April 7, 2024
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2Kosh Agarwal, Maria Buti, Florian van Bömmel, et al.
Hepatology Communications|February 26, 2025
Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis BFlorian van Bömmel, Thierry Verbinnen, Kosh Agarwal, et al.
Journal of Hepatology|May 16, 2026
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresHeiner Wedemeyer, Ed Gane, Kosh Agarwal, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
The Journal of Antimicrobial Chemotherapy|January 18, 2022
Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infectionEd J Gane, Christian Schwabe, Elina Berliba, et al.
Antimicrobial Agents and Chemotherapy|January 28, 2009
In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitorTse-I Lin, Oliver Lenz, Gregory Fanning, et al.
Environmental Toxicology and Chemistry|July 29, 2024
Occurrence and Environmental Risk Assessment of Contaminants of Emerging Concern in Brazilian Surface WatersThiessa M A Oliveira, Adrislaine S Mansano, Carlos A Holanda, et al.
Gut|November 5, 2025
Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT studyPatrick T F Kennedy, Scott Fung, Maria Buti, et al.
Clinical & Translational Immunology|April 22, 2026
An Ad26-MVA-BN-based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infectionsSelina Khan, Satish Boedhoe, Miranda Baert, et al.
Gastroenterology|April 29, 2020
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic InfectionFabien Zoulim, Oliver Lenz, Joris J Vandenbossche, et al.
The Lancet. Infectious Diseases|December 9, 2014
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trialK Rajender Reddy, Stefan Zeuzem, Fabien Zoulim, et al.
Journal of Hepatology|April 7, 2024
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2Kosh Agarwal, Maria Buti, Florian van Bömmel, et al.
Hepatology Communications|February 26, 2025
Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis BFlorian van Bömmel, Thierry Verbinnen, Kosh Agarwal, et al.
Journal of Hepatology|May 16, 2026
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresHeiner Wedemeyer, Ed Gane, Kosh Agarwal, et al.
Pageof 10